NCT04614467View on ClinicalTrials.gov

A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction

PHASE2TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 29, 2020

Primary Completion Date

September 28, 2022

Study Completion Date

September 28, 2022

Conditions
Coronary Microvascular DysfunctionCoronary Microvascular DiseaseMicrovascular Coronary Artery Disease
Interventions
BIOLOGICAL

CLBS16

GCSF-mobilized autologous CD34+ cells

BIOLOGICAL

Placebo

isotonic solution (no CD34+ cells)

Trial Locations (7)

30322

Emory University Hospital, Atlanta

32606

University of Florida - College of Medicine/ div of Cardiovascular Medicine, Gainesville

33021

Memorial Regional Hospital, Hollywood

45219

The Christ Hospital, Cincinnati

55407

Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis

55905

Mayo Clinic in Rochester, Rochester

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors
All Listed Sponsors
lead

Lisata Therapeutics, Inc.

INDUSTRY

NCT04614467 - A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction | Biotech Hunter | Biotech Hunter